Vutrisiran: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and HAS (France), among others, recommended or restricted vutrisiran, while AOTMIT (Poland) and DMC (Denmark) did not recommend it.
The record spans 3.8 years, opening at AWMSG (Wales) on 30 Sep 2022 and running to 2026.
CIPM (Spain) changed its position: not recommended on 15 Jun 2023, recommended by 20 May 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 24 of 27 records date from 2023 or later.
6 distinct indication wordings are recorded for vutrisiran by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 27 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess vutrisiran, on 30 Sep 2022; AOTMIT (Poland) did not open a file until 15 Jun 2026 — a wide spread of 3.8 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
7 of the 15 agencies here assessed vutrisiran more than once, CIPM (Spain) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
vutrisiran has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for vutrisiran reads 12 recommended, 6 not recommended, 3 restricted and 2 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 15 Jun 2026 | programu lekowego B.162 „Leczenie pacjentów z kardiomiopatią (ICD-10: E85, I42.1) | not recommended | source |
| AIFA (Italy) | 28 May 2026 | Amvuttra è indicato per il trattamento dell’amiloidosi da transtiretinawild-typeo ereditaria in pazienti adulti affetti … | innovative status not granted · reimbursed class H | source |
| CIPM (Spain) | 20 May 2026 | Indicaciones terapéuticas autorizadas: Tratamiento de la amiloidosis hereditaria por transtiretina en pacientes adultos … | financed by the SNS, on appeal | source |
| DMC (Denmark) | 29 Apr 2026 | Behandling af vildtype eller hereditær transthyretin-amyloidose hos voksne patienter med kardiomyopati | Ikke anbefalet, revurderes | source |
| HAS (France) | 4 Mar 2026 | Re-assessment following post-listing study results | SMR substantial · ASMR V | source |
22 further decisions for vutrisiran, across 12 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- tafamidis — divergent outcome (recommended vs not recommended) on a shared indication
- pitolisant — same ATC class N07X — Other nervous system
- fampridine — same ATC class N07X — Other nervous system
- omaveloxolone — same ATC class N07X — Other nervous system
- patisiran — same ATC class N07X — Other nervous system
- tofersen — same ATC class N07X — Other nervous system
Coverage: 27 decisions for vutrisiran from 15 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.